KALA BIO (NASDAQ:KALA) Rating Reiterated by Oppenheimer

KALA BIO (NASDAQ:KALA)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer in a report released on Monday, Benzinga reports. They currently have a $15.00 price target on the stock. Oppenheimer’s price objective would suggest a potential upside of 138.10% from the company’s current price.

Separately, HC Wainwright cut their price objective on KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, May 17th.

KALA BIO Trading Up 0.3 %

NASDAQ KALA opened at $6.30 on Monday. The stock’s 50-day simple moving average is $6.39 and its two-hundred day simple moving average is $6.86. KALA BIO has a twelve month low of $4.21 and a twelve month high of $14.50. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 4.92. The company has a market capitalization of $17.74 million, a price-to-earnings ratio of -0.42 and a beta of -2.03.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.40) by $1.24. Research analysts forecast that KALA BIO will post -14.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mark T. Iwicki sold 15,168 shares of the firm’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the completion of the transaction, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Mark T. Iwicki sold 7,392 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $6.09, for a total value of $45,017.28. Following the transaction, the chief executive officer now owns 278,923 shares of the company’s stock, valued at $1,698,641.07. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the sale, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,255 shares of company stock valued at $182,564. Company insiders own 13.40% of the company’s stock.

Institutional Investors Weigh In On KALA BIO

Several large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new stake in KALA BIO during the 4th quarter worth about $30,000. Knights of Columbus Asset Advisors LLC boosted its position in KALA BIO by 100.0% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 4,834 shares of the company’s stock valued at $34,000 after buying an additional 2,417 shares during the last quarter. Finally, SR One Capital Management LP acquired a new position in KALA BIO in the 2nd quarter worth approximately $3,146,000. Institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.